CEL-SCI & U.S. NAVY ADMINISTER MULTIKINE TO FIRST VOLUNTEER PATIENT IN PHASE I CLINICAL TRIAL FOR TREATMENT OF ANAL WARTS IN HIV/HPV CO-INFECTED PATIENTS

Print E-mail
Monday, 29 September 2014 12:11

Vienna, VA, September 29, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM) today announced the first volunteer patient has been enrolled and administered Multikine* (Leukocyte Interleukin, Injection) in a Institutional Review Board approved Phase I Clinical Trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women at the Naval Medical Center San Diego (NMCSD).

Read more...
 

Provectus Biopharmaceuticals’ PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress

Print E-mail
Wednesday, 24 September 2014 11:52

KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that the abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now available at https://www.webges.com/cslide/library/esmo/browse/search/8ct#9faD03sJ.

Read more...
 

ACCESS PHARMACEUTICALS ANNOUNCES EXCLUSIVE GLOBAL PLASMA THERAPEUTICS LICENSE, NEW MANAGEMENT AND NEW CORPORATE NAME

Print E-mail
Monday, 22 September 2014 09:47

Name Changed to PlasmaTech Biopharmaceuticals, Inc.

 

Proprietary, Disruptive Technology for the Bioidentical Therapeutics Business

 

Dallas, TX and New York, NY, September 22, 2014 - ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), has signed an exclusive, global license agreement with Plasma Technologies LLC ("PlasmaTech") for the development and commercialization of its proprietary plasma fractionation process.

Read more...
 

RELMADA THERAPEUTICS, INC. APPOINTS CHRISTOPHER W. JAMES AS SENIOR DIRECTOR OF CLINICAL DEVELOPMENT

Print E-mail
Thursday, 18 September 2014 19:04
New York, NY--Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Mr. Christopher W. James to the position of  Senior Director of Clinical Development.
Read more...
 

How to Pick Winning Biotechs Before the Herd

Print E-mail
Wednesday, 03 September 2014 19:34

Liana Moussatos of Wedbush Securities doesn't wait for the catalyst to strike.

Read more...
 

Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program

Print E-mail
Wednesday, 16 July 2014 11:51
NEW YORK--Actinium Pharmaceuticals, Inc . (nyse mkt:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers initiated development of an additional antibody construct labeled with actinium-225.
Read more...
 

PV-10 Immune Mechanism Data to Be Presented at the American Association for Cancer Research Annual Meeting

Print E-mail
Thursday, 06 March 2014 12:01
KNOXVILLE, Tenn.-- Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that data will be presented by researchers from Moffitt Cancer Center in a poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California.
Read more...
 


BioMedReports XOMA Initiates Trial of Gevokizumab; Sarepta Reports Favorable Safety Results of AVI-7100: Below is a look at ... http://t.co/S88hJTdtan
14hreplyretweetfavorite
BioMedReports Study says hepatitis C will be a rare disease by about 2036 http://t.co/SfrOoDv2CD
14hreplyretweetfavorite
BioMedReports Healthcare Review: Catalyst Pharmaceuticals, Can-Fite BioPharma, Acasti Pharmaceuticals, Northwest Biotherapeu... http://t.co/7OWLgqgTqM
17hreplyretweetfavorite
navigation

Newsletter

Benzinga.com supporter Seeking Alpha Certified